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Purpose of review
To critically appraise evidence on probiotic use for prevention and treatment of diarrhea
in children and adults.
Recent findings
Several randomized controlled trials and meta-analyses suggested that probiotics are
effective in primary and secondary prevention of gastroenteritis and its treatment.
Selected Lactobacillus strains had a modest, although significant effect in primary
prevention. Saccharomyces boulardii was effective in antibiotic-associated and in
Clostridium difficile diarrhea. There is evidence that it might prevent diarrhea in day-care
centers. Lactobacillus rhamnosus GG was associated with reduced diarrheal duration
and severity, more evident in case of childhood Rotavirus diarrhea. Similar, although
weaker, evidence was obtained with S. boulardii. Both strains are included in evidence-
based recommendations for gastroenteritis management in children. Data on other
Lactobacillus strains are preliminary. Probiotic efficacy was related to cause, early
administration and bacterial load, and their mechanisms were associated with
antiinfectious action in the intestine or, indirectly, to modulation of innate and adaptive
immunity.
Summary
Probiotics have gained a role as adjunctive treatment of infantile gastroenteritis together
with rehydration. Their efficacy is less convincing in adults, but promising in antibiotic-
associated diarrhea. However, evidence of efficacy is limited to a few strains.
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0267-1379Introduction
Probiotics may have preventive or therapeutic effects on
diarrhea of various etiologies. However, not all probiotics
are effective and physicians must select preparations with
proven efficacy. Here, we critically appraise recent data
on the prevention and treatment of diarrhea in relation to
cause. We also briefly discuss new data impinging on the
mechanisms governing the effects of probiotics. The role
of probiotics in diarrhea associated with inflammatory
bowel diseases and irritable bowel syndrome is not taken
into account in this review.
Primary prevention
As diarrhea is a very frequent problem in young infants
and children, probiotics have been proposed for the
prevention of community-acquired diarrhea. Six
randomized controlled trials (RCTs) are available.
The probiotics tested were Lactobacillus GG (LGG),
Streptococcus thermophilus in association with Bifidobacter-
ium breve or with Bifidobacterium lactis, B. lactis alone,
Lactobacillus casei DN-114 and Lactobacillus reuteri. The0267-1379  2008 Wolters Kluwer Health | Lippincott Williams & Wilkinsresults were not always statistically significant and were
of questionable clinical relevance. A double-blind RCT
performed in a large pediatric population in France
reported fewer episodes of dehydration, medical consul-
tation and need for formula shift in infants fed probiotic-
supplemented formula, although the incidence of diar-
rhea was similar to that of the control group [1]. A smaller
RCT in Israel found a reduction in the frequency and
duration of diarrhea in treated children [2]. These trials
provided evidence of a modest protective effect of
specific strains. Indirect evidence that targeting intesti-
nalmicroecology is effective in preventing diarrhea is the
finding of fewer intestinal infections in a cohort of
healthy infants fed prebiotics in the first year of life
[3]. The cost efficacy of such interventions remains to
be established.
Secondary prevention
Secondary prevention involves selected conditions,
limited in duration, that are associated with an
increased risk of diarrhea rather than with host-related
factors.DOI:10.1097/MOG.0b013e32831b4455
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Antibiotic-associated diarrhea (AAD) occurs in about
5–25% of adult patients and 11–40% of children upon
administration of broad-spectrum antibiotics. Clostri-
dium difficile is a major agent, although diarrhea may
be related to general changes in intestinal microflora. A
systematic review [4] and a meta-analysis of RCTs [5]
provided evidence of a moderate beneficial effect of
LGG, Saccharomyces boulardii and a combination of B.
lactis and S. thermophilus in preventing AAD. A recent
Cochrane review of 10 RCTs carried out in 1015 treated
and 971 control children reported a significant reduction
in the incidence of AAD [Relative risk (RR) 0.49; 95%
confidence interval (CI) 0.32–0.74], confirming the
efficacy of LGG and S. boulardii [6]. The subgroup
analyses provided evidence that probiotic dose may be
responsible for the observed clinical and statistical
heterogeneity of results. Interestingly, of the eight
studies that provided dosage information, five studies
in which children received 5–40 billion bacteria/yeast/
day showed that probiotics had preventive effects (RR
0.35; 95% CI 0.25 to 0.47), whereas the combined
results of three studies using less than 5 billion col-
ony-forming unit (CFU) bacteria/yeast/day were not
significant (RR 0.89; 95% CI 0.53 to 1.48,
I2¼ 61.4%). The number-needed-to-treat was between
seven and 10. As suggested by the Cochrane review,
more data are needed to consider the routine use of
probiotics to prevent AAD in children started on large
spectrum antibiotics. In particular, cost-benefit data are
strongly needed.
Two recent double-blind RCTs suggested that other
strains were effective in preventing AAD. The first,
conducted on 135 adults, showed that a drink containing
L. casei, Lactobacillus bulgaricus and S. thermophilus twice
daily prevented AAD and diarrhea caused by C. difficile
(number-needed-to-treat five and seven, respectively)
[7]. The second was a pediatric trial in which Lactobacillus
rhamnosus (strains E/N, Oxy and Pen) reduced the risk
of any diarrhea in children undergoing antimicrobial
therapy for common infectious diseases [8].
The role of probiotics in C. difficile-associated diarrhea is
still unclear. S. boulardii was found to be significantly
effective in treating C. difficile diarrhea [9]. The benefit of
probiotics in C. difficile diarrhea was mostly seen in adults
and, particularly, in subgroups characterized by severe
disease [10]. Despite the moderate evidence obtained in
adults, the use of probotics to specifically treat or prevent
C. difficile diarrhea has not been evaluated in a RCT in
children. A recent meta-analysis showed that LGG and S.
boulardii might be useful in treating or preventing recur-
rences of C. difficile diarrhea [11]. Nonetheless, the
heterogeneity of the studies makes it difficult to draw
definite conclusions.Nosocomial and day-care center diarrhea
Nosocomial diarrhea may prolong hospital stay and
increase medical costs. It is commonly caused by Rota-
virus and less frequently by C. difficile. Earlier and incon-
sistent data suggesting that probiotics may reduce the risk
of nosocomial diarrhea were summarized in a recent
review, and the conflicting results may have been related
to the strain and dose of probiotic used [12]. Five RCTs
have been published on the prevention of diarrhea in day-
care centers. The probiotics tested were LGG, B. lactis
(alone or combined with S. thermophilus) and Lactobacillus
thermophilus. Efficacy was modest and inconsistent and
was detected for some strains only. A narrative review
[12] and a recent systematic review [13] agreed that
evidence in favor of probiotics for prevention of diarrhea
in day-care centers and for nosocomial diarrhea is not
sufficient to recommend their routine use.
Traveler’s diarrhea
Travel is a risk factor for infectious gastroenteritis. A
recent meta-analysis revealed evidence of a protective
effect by S. boulardi and by mixture of Lactobacillus
acidophilus and Bifidobacterium bifidum [14]. However,
evidence of the efficacy of probiotics in the prevention
of traveler’s diarrhea is preliminary.
Diarrhea related to nonantibiotic treatment
Drugs and other treatment administered for noninfec-
tious diseases such as cancer may induce diarrhea. A
novel field of application of probiotics is prevention of
iatrogenic diarrhea related to treatment toxicity. Lactic
acid producing bacteria reduce the risk of radiation-
induced diarrhea. Prophylactic administration of
VSL#3 (a mixture of four species of lactobacilli, three
species of bifidobacteria and S. thermophilus) reduced the
incidence of radiation-associated enteritis in a placebo-
controlled trial that included 500 patients who underwent
postoperative radiation therapy [15]. Some probiotic
strains were found to be beneficial in cancer drug-
induced diarrheas, namely, VSL#3 prevented irinote-
can-related diarrhea (in rats) and LGG reduced the
frequency of severe diarrhea caused by 5FU-based che-
motherapy [16].
Treatment of intestinal infections
Although the standard treatment of acute diarrhea
remains to be an oral rehydration solution (ORS), pro-
biotics have gained an important role as adjuvant therapy.
A large number of trials, including randomized and
controlled, and several accurate meta-analyses reported
that probiotics exerted antidiarrheal effects particularly in
children. A wide pattern of strains, schedules, doses and
conditions have been tested. The outcomes most widely
considered were duration of diarrhea, duration of hospi-
talization and severity of diarrhea, with some trials eval-
uating ORS intake, number of vomiting episodes and
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Figure 1 Effects of different probiotic strains on the duration of
acute diarrhea in children
¼P<0.001 compared with oral rehydration solution alone (Mann–
Whitney U test). The figure shows the effects on the duration of diarrhea
of five different probiotic preparations administered in addition to oral
rehydration solution. The control group received oral rehydration solution
only. The total duration of diarrhea is significantly lower in children
receiving Lactobacillus rhamnosus GG (group 1) and in those receiving
the bacterial mix (group 4) than in patients receiving oral rehydration
solution alone. These results demonstrate that not all commercially
available probiotic preparations are effective in children with acute
diarrhea. , Oral rehydration solution (ORS) alone; , Lactobacillus
casei subsp. rhamnosus GG; , Saccharomyces boulardi; , Bacillus
clausii; , Lactobacillus delbrueckii var. bulgaricus, Lactobacillus acid-
ophilus, Streptococcus thermophilus, Bifidobacterium bifidum; ,
Enterococcus faecium Sf 68. Reproduced with permission [22].stool volumes. Despite the broad spectrum of design and
conditions, nearly all studies showed some positive
effects on diarrhea, with statistically significant benefits
or moderate clinical benefits mainly in infants and young
children. A number of strains have been tested, but proof
of efficacy is compelling only for a few. LGG and S.
boulardii are the strains most widely tested and also are
the most effective. The efficacy of LGG as an adjunctive
treatment of diarrhea is now considered conclusive.
A recent meta-analysis of RCTs [17] showed that LGG
is associated with a reduced duration of diarrhea, particu-
larly that induced by Rotavirus. LGG also reduced the
risk of persistent diarrhea (lasting>7 days) and shortened
the duration of hospitalization compared with placebo.
Interestingly, probiotic administration is generally effec-
tive in a population irrespective of the cause of diarrhea.
However, when the cause of diarrhea is known, the
efficacy tends to be confined to viral diarrhea and, less
commonly, to ‘unknown etiology’, whereas it does not
extend to bacterial diarrhea. An exception is a recent
double-blind RCT conducted in parallel with an exper-
imental study of L. acidophilus strain LB, which showed a
reduction by 1 day of bacteria-induced diarrhea [18]. This
trial was performed with a probiotic preparation contain-
ing heat-killed strains.
Five RCTs testing S. boulardii in a total of 619 patients
were included in a recent meta-analysis [19], and the
authors concluded that S. boulardii exerts a moderate
clinical benefit by significantly reducing the duration of
diarrhea and the risk of diarrhea longer than 1 week.
Other strains have been tested including Lactobacillus
reuteri, L. acidophilus LB, a mixture of S. thermophilus,
Lactobacillus bulgaricus and others. Two recent multicen-
ter RCTs, each of which included more than 100 children
treated with Escherichia coli strain Nissle 1917, reported a
significant reduction of the duration of acute diarrhea
[20,21].
The only head-to-head comparative trial performed
with different strains was a single-blind RCT performed
in Italy on children aged from 3 to 36 months with acute
gastroenteritis [22]. The trial compared the effects of
five probiotic preparations, namely, LGG, S. boulardii,
Bacillus clausii, a mixture of L. bulgaricus, S. thermophilus,
L. acidophilus and B. bifidum and finally Enterococcus
faecium SF68. The control group received oral rehydra-
tion solution only. Diarrhea duration and severity were
significantly reduced after the administration of LGG
and the mix of four strains versus children who received
ORS alone (Fig. 1). LGG was more effective than the
mix, but the difference was not significant. The other
three preparations did not affect symptom duration.
These results confirm that the efficacy of probiotics is
related to the strain, however, dosage is also important.An early meta-analysis reported dose-related efficacy for
lactobacilli preparations against gastroenteritis [23].
This important concept emerged again from a recent
review [12]. Probiotic efficacy was correlated in a linear
fashion with bacterial load, the minimal effective dose
being at least 10 billions CFU/day. An example of the
importance of the dose comes from a RCT conducted in
India [24], in which a dose of only 60million CFU of
LGG, one of the lowest ever used in a clinical trials, was
administered twice a day and did not affect the fre-
quency and duration of diarrhea or vomiting in children
with acute diarrhea. However, interestingly, the same
dose significantly reduced the risk of persistent diar-
rhea, thus showing that efficacy is not merely a matter
of dose, but also depends on the outcome parameter
considered [25].
In conclusion, data from several meta-analyses show that
the effects of probiotics in acute diarrhea in children are
strain-dependent and dose-dependent, being generally
greater with doses more than 1010–1011CFU, highly
significant for watery diarrhea and viral gastroenteritis,
but not for invasive bacterial diarrhea, more evident when
treatment is initiated early in the course of disease and
more evident in children in developed than in
developing countries.
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document, namely the Guidelines For the Manage-
ment of Acute Gastroenteritis produced by a joint
committee from the European Society for Pediatric
Gastroenterology, Hepatology and Nutrition (ESP-
GHAN) and the European Society for Pediatric Infec-
tious Disease (ESPID) [26]. The document was
developed through an evidence-based systematic
review approach that incorporated tables of evidence
with their grading. The guidelines state that ‘probiotics
may be an effective adjunct to the management of
diarrhea. However, because of the lack of efficacy for
many preparations, only the use of probiotic strains
with proven efficacy and in appropriate doses is
suggested for the management of acute diarrhea in
European children as an adjunct to rehydration
therapy’. The evidence of efficacy for LGG was rated
as IA, which is the maximum, and that for S. boulardii
IIB, corresponding to a strong level of evidence based
on meta-analysis of RCTs and properly designed
RCTs of appropriate size, respectively. A similar con-
clusion appears in the recent recommendations for the
clinical use of probiotics based on the Yale University
Workshop update of 2007 in which the recommen-
dations were graded ‘A’, ‘B’, ‘C’ or no category, based
on expert opinion [27].
Probiotics have also been tested in HIV/AIDS patients,
many of whom suffer from debilitating infectious and
noninfectious diarrhea. Although probiotics did not sig-
nificantly affect gastrointestinal symptoms in a well
designed RCT that included HIV-infected patients
undergoing antiretroviral therapy [28], a recent clinical
trial showed that probiotic yogurt containing some Lac-
tobacilli strains resolved moderate diarrhea and increased
CD4 cells/ml in HIV/AIDS patients [29].
Safety issues
Probiotics are generally regarded as being safe, and side
effects in ambulatory care have rarely been reported.
Safety issues are related to bacterial translocation and
sepsis, and to the risk of carrying antibiotic resistance
transposons that may spread resistance to antibiotics. The
latter has been reported for some probiotics, among
which are L. reuteri ATCC 55730 and Enterococcus faecium
[30,31].
Mechanisms of action of probiotics
The rationale for using probiotics is based on the
assumption that they modify the composition of
colonic microflora and counteract enteric pathogens.
However, there are two main views as to how probiotics
counteract diarrhea. According to one theory, probiotics
act locally (at intestinal level). According to the other
theory, probiotics act by modulating the immune
response.At local level, probiotics:(1) compete with pathogens for nutrients and receptors
[32];(2) induce hydrolysis of toxins and receptors [32];
(3) induce production of antimicrobial substances
(including peptides of the innate immune system)
[32];(4) induce production of organic acids and modulation of
nitric oxide synthesis [32];(5) regulate intestinal permeability by modulating the
epithelial tight junctions [33];(6) exert a trophic action on the intestinal mucosa, which
leads to brush border enzyme activation, stimulation
of glucose absorption and antiapoptotic effects on the
enterocyte [34];(7) inhibit selected intracellular mechanisms involved in
viral replication (such as MEK, PKA, p38 MAPK)
[34].On the other hand, an increasing body of evidence
supports the concept that probiotics modulate the
immune response. Dendritic cells and toll-like receptor
molecules are crucial factors in this process. These cells
receive signals from structural lipopolysaccharides, gly-
copeptides and CpG DNA of probiotic strains and trans-
duce them in order to regulate the production of innate
immunity peptides that, in turn, exert antimicrobial
activity or modulate adaptive immunity [35]. Selected
probiotics promote specific antibody responses against
given pathogens. This is the case of S. boulardii that, apart
from producing a 54-kD protease that hydrolyzes the A
and B toxins of C. difficile and their intestinal receptors,
also stimulates the production of specific IgG and IgA
antitoxin A produced by the same pathogen [35]. LGG
increases the mucosal production of specific antirotavirus
sIgA and modulates the mucosal inflammatory response
to pathogens by stimulating the production of anti-
inflammatory IL-10 and IL-4 and by inhibiting the pro-
duction of proinflammatory TNF-a, IL-6 and IFN-g
[36]. This process affects transepithelial ion fluxes,
and hence diarrhea, as proinflammatory cytokines induce
a potent ion secretory effect at intestinal level and their
inhibition reduces fluid losses in children with inflam-
matory diarrhea.
Specific Lactobacillus strains activate muciparous cell
genes, which leads to an increase in the thickness of
the enterocyte mucus layer, thereby preventing the
adhesion of pathogenic E. coli. LGG negatively modu-
lates Shiga toxin 2A production by enterohemorrhagic E.
coli (EHEC) 0157:H7 through a mechanism that involves
pH changes mediated by the production of organic acids
[37]. Finally, strains of the same probiotic species may
have different mechanisms of action depending on
the pathogen.
22 Gastrointestinal infectionsMost probiotic effects have been demonstrated in exper-
imental studies and only a few in clinical studies. How-
ever, it remains to be established whether the antidiar-
rheal effects of different probiotic strains are governed by
a single mechanism.Conclusion
The evaluation of the effects of probiotics has progressed
from empiricism to science, and the efficacy of specific
strains in acute gastroenteritis is demonstrated in several
RCTs and meta-analyses. The increasing use of probio-
tics is linked to the concept of ‘naturality’, which fulfills
the desire of customers to take medicines free from side
effects that is largely true for probiotics. Novel fields of
application for probiotics may emerge, including func-
tional bowel disorders and inflammatory or allergic dis-
eases that are responsible for chronic, potentially severe
diarrhea in both adults and children. This is likely to
support the concept of using specific strains for
specific conditions.
Acknowledgements
We are grateful to Jean Ann Gilder for editing the text.References and recommended reading
Papers of particular interest, published within the annual period of review, have
been highlighted as:
 of special interest
 of outstanding interest
Additional references related to this topic can also be found in the Current
World Literature section in this issue (p. 77).
1 Thibault H, Aubert-Jacquin C, Goulet O. Effects of long-term consumption of a
fermented infant formula (with Bifidobacterium breve c50 and Streptococcus
thermophilus 065) on acute diarrhea in healthy infants. J Pediatr Gastro-
enterol Nutr 2004; 39:147–152.
2 Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on
infections in child care centers: comparison of two probiotic agents. Pedia-
trics 2005; 115:5–9.
3 Bruzzese E, Volpicelli M, Squaglia M, et al. Impact of prebiotics on human
health. Dig Liver Dis 2006; 38 (Suppl 2):S283–S287.
4 Szajewska H, Setty M, Mrukowicz J, et al. Probiotics in gastrointestinal
diseases in children: hard and not-so-hard evidence of efficacy. J Pediatr
Gastroenterol Nutr 2006; 42:454–475.
5 Szajewska H, Ruszczynski M, Radzikowski A. Probiotics in the prevention of
antibiotic-associated diarrhea in children: a meta-analysis of randomized
controlled trials. J Pediatr 2006; 149:367–372.
6

Johnston BC, Supina AL, Ospina M, et al. Probiotics for the prevention of
pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2007;
2:CD004827.
A recent and complete systematic review that reports the efficacy of selected
probiotics in the prevention of antibiotic-associated diarrhea and underlines the
important role of the dose-response effect.
7 Hickson M, D’Souza AL, Muthu N, et al. Use of probiotic Lactobacillus
preparation to prevent diarrhoea associated with antibiotics: randomised
double blind placebo controlled trial. BMJ 2007; 335:80.
8

Ruszczynski M, Radzikowski A, Szajewska H, et al. Clinical trial: effectiveness
of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of
antibiotic-associated diarrhoea in children. Aliment Pharmacol Ther 2008;
28:154–161.
Awelldesignedrandomizedcontrolled trial thatdemonstrates thebeneficialeffectsof
new probiotic strains for the prevention of antibiotic-associated diarrhea in children.
9 Czerucka D, Piche T, Rampal P. Review article: yeast as probiotics –
Saccharomyces boulardii. Aliment Pharmacol Ther 2007; 26:767–778.10 Dendukuri N, Costa V, McGregor M, et al. Probiotic therapy for the prevention
and treatment of Clostridium difficile disease: a systematic review. CMAJ
2005; 173:167–170.
11 Segarra-Newnham M. Probiotics forClostridium difficile-associated diarrhea:
focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii. Ann
Pharmacother 2007; 41:1212–1221; Review.
12

Guandalini S. Probiotics for children with diarrhea: an update. J Clin Gastro-
enterol 2008; 42 (Suppl 2):S53–S57.
A complete and useful review that focuses on the efficacy of probiotics for diarrhea
of different etiologies in children in different settings.
13 Mrukowicz J, Szajewska H, Vesikari T. Options for the prevention of rotavirus
disease other than vaccination. J Pediatr Gastroenterol Nutr 2008; 46 (Suppl
2):S32–S37.
14 McFarland LV. Meta-analysis of probiotics for the prevention of traveler’s
diarrhea. Travel Med Infect Dis 2007; 5:97–105.
15 Delia P, Sansotta G, Donato V, et al. Use of probiotics for prevention of
radiation-induced diarrhea. World J Gastroenterol 2007; 13:912–915.
16 Osterlund P, Ruotsalainen T, Korpela R, et al. Lactobacillus supplementation
for diarrhoea related to chemotherapy of colorectal cancer: a randomised
study. Br J Cancer 2007; 97:1028–1034.
17

Szajewska H, Skorka A, Ruszczynski M, et al.Meta-analysis: Lactobacillus GG
for treating acute diarrhoea in children. Aliment Pharmacol Ther 2007;
25:871–881.
A complete meta-analysis of the role of LGG in the therapy of acute diarrhea in
children.
18 Lievin-Le Moal V, Sarrazin-Davila L, Servin AL. An experimental study and a
randomized, double-blind, placebo-controlled clinical trial to evaluate the
antisecretory activity of Lactobacillus acidophilus strain LB against nonrota-
virus diarrhea. Pediatrics 2007; 120:e795–e803.
19

Szajewska H, Skorka A, Dylag M. Meta-analysis: Saccharomyces boulardii for
treatingacutediarrhoea inchildren.AlimentPharmacolTher2007;25:257–264.
A complete meta-analysis on the role of S. boulardii in the therapy of acute diarrhea
in children.
20 Henker J, Laass M, Blokhin BM, et al. The probiotic Escherichia coli strain
Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. Eur J Pediatr
2007; 166:311–318.
21 Henker J, Laass M, Blokhin BM, et al. Probiotic Escherichia coli Nissle 1917
versus placebo for treating diarrhea of greater than 4 days duration in infants
and toddlers. Pediatr Infect Dis J 2008; 27:494–499.
22

Canani RB, Cirillo P, Terrin G, et al. Probiotics for treatment of acute diarrhoea
in children: randomised clinical trial of five different preparations. BMJ 2007;
335:340.
The only head-to-head trial with different probiotic preparations. It shows that many
probiotic strains are effective and not all probiotics are interchangeable in their
efficacy.
23 Van Niel CW, Feudtner C, Garrison MM, et al. Lactobacillus therapy for acute
infectious diarrhea in children: a meta-analysis. Pediatrics 2002; 109:678–
684.
24 Basu S, Chatterjee M, Ganguly S, et al. Efficacy of Lactobacillus rhamnosus
GG in acute watery diarrhoea of Indian children: a randomised controlled trial.
J Paediatr Child Health 2007; 43:837–842.
25 Basu S, Chatterjee M, Ganguly S, et al. Effect of Lactobacillus rhamnosus
GG in persistent diarrhea in Indian children: a randomized controlled trial.
J Clin Gastroenterol 2007; 41:756–760.
26

Guarino A, Albano F, Ashkenazi S, et al. European Society for Paediatric
Gastroenterology, Hepatology, and Nutrition/European Society for paediatric
infectious diseases evidence-based guidelines for the management of acute
gastroenteritis in children in Europe: executive summary. J Pediatr Gastro-
enterol Nutr 2008; 46:619–621.
This is the most recent and complete evidence-based document for the manage-
ment of acute gastroenteritis in pediatric age and the first guideline to recommend
probiotics as an effective adjunct to the management of diarrhea.
27 Floch MH,Walker A, Guandalini S, et al. Recommendations for probiotic use-
2008. J Clin Gactroenterol 2008; 42 (Suppl 2):S104–S108.
28 Salminen MK, Tynkkynen S, Rautelin H, et al. The efficacy and safety of
probiotic Lactobacillus rhamnosus GG on prolonged, noninfectious diarrhea
in HIV Patients on antiretroviral therapy: a randomized, placebo-controlled,
crossover study. HIV Clin Trial 2004; 5:183–191.
29 Anukam KC, Osazuwa EO, Osadolor HB, et al. Yogurt containing probiotic
Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 helps resolve moderate
diarrhea and increases CD4 count in HIV/AIDS patients. J Clin Gastroenterol
2008; 42:239–243.
30 Egervarn M, Danielsen M, Roos S, et al. Antibiotic susceptibility profiles of
Lactobacillus reuteri and Lactobacillus fermentum. J Food Prot 2007;
70:412–418.
Probiotics as prevention and treatment for diarrhea Guarino et al. 2331 Kayser FH. Safety aspects of enterococci from the medical point of view. Int J
Food Microbiol 2003; 88:255–262.
32 Lemberg DA, Ooi CY, Day AS. Probiotics in paediatric gastrointestinal
diseases. J Paediatr Child Health 2007; 43:331–336.
33 Seth A, Yan F, Polk DB, Rao RK. Probiotics ameliorate the hydrogen peroxide-
induced epithelial barrier disruption by a PKC- and MAP kinase-dependent
mechanism.AmJPhysiolGastrointestLiverPhysiol2008;294:G1060–G1069.
34 Yan F, Cao H, Cover TL, et al.Soluble proteins produced by probiotic bacteria
regulate intestinal epithelial cell survival and growth. Gastroenterology 2007;
132:562–575.35

Walker WA. Mechanisms of action of probiotics. Clin Infect Dis 2008;
46:S87–S91.
A very interesting review of the mechanisms of action of probiotics.
36

Jonkers D, Stockbru¨gger R. Review article: probiotics in gastrointestinal and
liver diseases. Aliment Pharmacol Ther 2007; 26:133–148.
This is an exhaustive review of the effects of probiotics in gastrointestinal and liver
diseases.
37 Carey CM, Kostrzynska M, Ojha S, Thompson S. The effect of probiotics and
organic acids on Shiga-toxin 2 gene expression in enterohemorrhagic Es-
cherichia coli O157:H7. J Microbiol Methods 2008; 73:125–132.
